MedPath

Modafinil

Generic Name
Modafinil
Brand Names
Provigil
Drug Type
Small Molecule
Chemical Formula
C15H15NO2S
CAS Number
68693-11-8
Unique Ingredient Identifier
R3UK8X3U3D
Background

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.

Indication

To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
Associated Therapies
-
Clinical Trials
Related News

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: Modafinil
First Posted Date
2007-10-19
Last Posted Date
2009-02-24
Lead Sponsor
Veterans Medical Research Foundation
Target Recruit Count
26
Registration Number
NCT00546403
Locations
🇺🇸

VA Healthcare System, Department of Psychiatry, San Diego, California, United States

A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence

Phase 2
Completed
Conditions
Methamphetamine Addiction
Interventions
Drug: modafinil
First Posted Date
2007-10-03
Last Posted Date
2013-06-03
Lead Sponsor
California Pacific Medical Center Research Institute
Target Recruit Count
20
Registration Number
NCT00538655
Locations
🇺🇸

CPMC - St. Luke's Hospital ~ 7th Floor/ Addiction Pharmacology Research Lab, San Francisco, California, United States

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

Phase 2
Completed
Conditions
Methamphetamine Dependence
Interventions
Drug: Placebo
Drug: Modafinil
First Posted Date
2007-08-24
Last Posted Date
2017-04-07
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
210
Registration Number
NCT00520286
Locations
🇺🇸

Powell Chemical Dependency Center, Des Moines, Iowa, United States

🇺🇸

Matrix Institute on Addictions, Tarzana, California, United States

🇺🇸

University of Colorado Health Sciences Center, Denver, Colorado, United States

and more 5 locations

Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI

Not Applicable
Conditions
Traumatic Brain Injury
Severe Traumatic Brain Injury
First Posted Date
2007-06-21
Last Posted Date
2007-07-25
Lead Sponsor
Kessler Foundation
Target Recruit Count
20
Registration Number
NCT00489892
Locations
🇺🇸

Kessler Medical Rehabilitation Research & Education Corporation, West Orange, New Jersey, United States

Modafinil vs Placebo for the Treatment of Methamphetamine Dependence

Phase 2
Completed
Conditions
Methamphetamine Dependence
Interventions
Drug: Placebo
Drug: Modafinil
First Posted Date
2007-05-04
Last Posted Date
2020-03-02
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
71
Registration Number
NCT00469508
Locations
🇺🇸

UCLA Vine Street Clinic, Hollywood, California, United States

Substance Abuse Pre-Treatment Screening Study

Recruiting
Conditions
Cocaine Abuse
Alcohol Dependence
Cocaine Dependence
Substance Abuse
Opiate Dependence
Interventions
Drug: modafinil
Drug: d-amphetamine
Drug: L-Dopa
Drug: Naltrexone
First Posted Date
2007-02-22
Last Posted Date
2023-12-20
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
7500
Registration Number
NCT00439049
Locations
🇺🇸

University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas, United States

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

Phase 2
Completed
Conditions
Narcolepsy
Interventions
Drug: JNJ-17216498
Drug: Modafinil
First Posted Date
2007-01-22
Last Posted Date
2014-05-23
Lead Sponsor
Alza Corporation, DE, USA
Target Recruit Count
16
Registration Number
NCT00424931

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

Phase 4
Completed
Conditions
Schizoaffective Disorder
Schizophrenia
Interventions
Drug: Placebos
Drug: modafinil
First Posted Date
2007-01-18
Last Posted Date
2017-09-29
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
33
Registration Number
NCT00423943
Locations
🇺🇸

University of California Los Angeles School of Medicine, Los Angeles, California, United States

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

Phase 3
Terminated
Conditions
Brain Tumor
Interventions
Drug: SR Methylphenidate
Drug: IR Methylphenidate
Drug: Modafinil
First Posted Date
2007-01-05
Last Posted Date
2020-09-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
34
Registration Number
NCT00418691
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

Not Applicable
Withdrawn
Conditions
Parkinson's Disease
First Posted Date
2006-10-29
Last Posted Date
2015-06-26
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00393562
Locations
🇺🇸

Philadelphia, OPC, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy